MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology

PLoS ONE

Volumn 3, Issue 2, 2008, Pages

  Mallajosyula, Jyothi K ^a   Kaur, Deepinder ^a   Chinta, Shankar J ^a   Rajagopalan, Subramanian ^a   Rane, Anand ^a   Nicholls, David G ^a   Di Monte, Donato A ^b   Macarthur, Heather ^c   Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b PARKINSON S INSTITUTE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIOXIDANT; EUK 189; HYDROGEN PEROXIDE; MINOCYCLINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SELEGILINE; SUPEROXIDE; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CELL ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; EMBRYO; FEMALE; LOCOMOTION; MALE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PARKINSON DISEASE; RISK FACTOR; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; ANIMAL; BRAIN; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; MOTOR ACTIVITY; NERVE CELL; PATHOLOGY;

ANIMALIA; MURINAE; MUS MUSCULUS;

ANIMALS; ASTROCYTES; BRAIN; DOPAMINE; GENE EXPRESSION REGULATION; MICE; MICE, TRANSGENIC; MONOAMINE OXIDASE; MOTOR ACTIVITY; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 45749101293     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001616     Document Type: Article

References (62)

1. Westlund KN, Denney RM, Rose RM, Abell CW (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25: 439-456.
2. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230: 181-183.
3. Levitt P, Pintar JE, Breakefield XO (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and secrotonergic neurons. Proc Natl Acad Sci U S A 79: 6385-6389.
4. Saura J, Richards JG, Mahy N (1994) Age-related changes on MAO in Bl/C57 mouse tissues: a quantitative radioautographic study. J Neural Transm Suppl 41: 89-94.
5. Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49: 1-20.
6. Riederer P, Konradi C, Schay V, Kienzl E, Birkmayer G, et al. (1987) Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol 45: 111-118.
7. Gerlach M, Youdim MB, Riederer P (1996) Pharmacology of selegiline. Neurology 47: S137-145.
8. Vindis C, Seguelas MH, Lanier S, Parini A, Cambon C (2001) Dopamine induces ERK activation in renal epithelial cells through H2O2 produced by monoamine oxidase. Kidney Int 59: 76-86.
9. Cohen G, Farooqui R, Kesler N (1997) Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci U S A 94: 4890-4894.
10. Adams JD Jr, Odunze IN (1991) Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 10: 161-169.
11. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59: 1609-1623.
12. Raps SP. Lai JC. Hertz L. Cooper AJ (1989) Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res 493: 398-401.
13. Sagara JI, Miura K, Bannai S (1993) Maintenance of neuronal glutathione by glial cells. J Neurochem 61: 1672-1676.
14. Makar TK, Nedergaard M, Preuss A, Gelbard AS, Perumal AS, et al. (1994) Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in antioxidative processes in the brain. J Neurochem 62: 45-53.
15. Kang Y, Oiao X, Jurma O, Knusel B, Andersen JK (1997) Cloning/brain localization of mouse glutamylcysteine synthetase heavy chain mRNA. Neuroreport 8: 2053-2060.
16. Buckman TD, Sutphin MS, Mitrovic B (1993) Oxidative stress in a clonal cell line of neuronal origin: effects of antioxidant enzyme modulation. J Neurochem 60: 2046-2058.
17. Behl C, Davis JB, Lesley R, Schubert D (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77: 817-827.
18. Whittemore ER, Loo DT, Cotman CW (1994) Exposure to hydrogen peroxide induces cell death via apoptosis in cultured rat cortical neurons. Neuroreport 5: 1485-1488.
19. Wei Q, Yeung M, Jurma OP, Andersen JK (1996) Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. J Neurosci Res 46: 666-673.
20. Damier P, Kastner A, Agid Y, Hirsch EC (1996) Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Neurology 46: 1262-1269.
21. Soong NW, Hinton DR, Cortopassi G, Arnheim N (1992) Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat Genet 2: 318-323.
22. Kumar MJ, Nicholls DG, Andersen JK (2003) Oxidative alpha-ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson's disease. J Biol Chem 278: 46432-46439.
23. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, et al. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306.
24. Przedborski S, Vila M (2003) The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 991: 189-198.
25. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69: 1322-1325.
26. Wu RM, Murphy DL, Chiueh CC (1996) Suppression of hydroxyl radical formation and protection of nigral neurons by 1-deprenyl (selegiline). Ann N Y Acad Sci 786: 379-390.
27. Magyar K, Szende B (2004) (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 25: 233-242.
28. Szende B, Bokonyi G, Bocsi J, Keri G, Timar F, et al (2001) Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. J Neural Transm 108: 25-33.
29. Shoulson I (1992) An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group. Eur Neurol 32 Suppl 1: 46-53.
30. LeWitt PA (1994) Clinical trials of neuroprotection in Parkinson's disease: longterm selegiline and alpha-tocopherol treatment. J Neural Transm Suppl 43: 171-181.
31. Schneider E (1995) DATATOP-study: significance of its results in the treatment of Parkinson's disease. J Neural Transm Suppl 46: 391-397.
32. Parkinson_Study_Group, (1998) Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Ann Neurol 43: 318-325.
33. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5): 2283-2301.
34. Zoccarato F, Toscano P, Alexandre A (2005) Dopamine-derived dopamino-chrome promotes H(2)O(2) release at mitochondrial complex I: stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease. J Biol Chem 280: 15587-15594.
35. Pickel VM, Johnson E, Carson M, Chan J (1992) Ultrastructure of spared dopamine terminals in caudate-putamen nuclei of adult rats neonatally treated with intranigral 6-hydroxydopamine. Brain Res Dev Brain Res 70: 75-86.
36. Nirenberg MJ, Chan J, Liu Y, Edwards RH, Pickel VM (1996) Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 16: 4135-4145.
37. Nirenberg MJ, Vaughan RA, Uhl GR, Kohar MJ, Pickel VM (1996) The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 16: 436-447.
38. Andrews ZB, Horvath B, Barnstable CJ, Elsworth J, Yang L, et al. (2005) Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. J Neurosci 25: 184-491.
39. Ochs SD, Westfall TC, Macarthur H (2005) The separation and quantification of aminochromes using high-pressure liquid chromatography with electrochemical detection. J Neurosci Methods 142: 201-208.
40. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291.
41. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, et al. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46: 598-605.
42. McGeer PL, Schwab C, Parent A, Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol 54: 599-604.
43. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, et al. (2003) Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23: 10756-10764.
44. Peng J, Xie L, Stevenson FF, Melov S, Di Monte DA, et al. (2006) Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration. J Neurosci 26: 11644-11651.
45. Imai Y, Kohsaka S (2002) Intracellular signaling in M-CSF-induced microglia activation: role of Ibal, Glia 40: 164-174.
46. Stence N, Waite M, Dailey ME (2001) Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. Glia 33: 256-266.
47. Youdim MB, Bakhte YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147 Suppl 1: S287-296.
48. Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, et al. (2003) Neuroprotective strategies in Parkinson's disease : an update on progress. CNS Drugs 17: 729-762.
49. Irwin I, Finnegan KT, Delanney LE, Di Monte D, Langston JW (1992) The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MFTP in C57BL/6 mice: a critical reassessment. Brain Res 572: 224-231.
50. Cohen G (1983) The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 19: 89-103.
51. Olanow CW (1993) A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. Mov Disord 8 Suppl 1: S1-7.
52. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, et al. (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15: 991-998.
53. Schneider JS, Denaro, FJ (1988) Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J Neuropathol Exp Neurol 47: 452-458.
54. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, et al. (2003) Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 964: 288-294.
55. Miller JH. (1972) Experiments in Molecular Genetics, Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press.
56. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909.
57. Smith DW, Friedmann T (2004) Discrepant effects of culture conditions on survival and function of dopaminergic neurons. Neuroreport 15: 1025-1028.
58. Docherty M, Bradford HF, Cash CD, Ehret M, Maitre M, et al. (1991) Isolation of monoaminergic synaptosomes from rat brain by immunomagnetophoresis. J Neurochem 56: 1569-1580.
59. Budd DC, Nicholls DG (1995) Protein kinase C-mediated suppression of the presynaptic adenosine Al receptor by a facilitatory metabotropic glutamate receptor. J Neurochem 65: 615-621.
60. Trounce IA, Kim YL, Jun AS, Wallace VC (1996) Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 264: 484-509.
61. Peng J, Wu Z, Wu Y, Hsu M, Stevenson FF, et al. (2002) Inhibition of caspases protects cerebellar granule cells of the weaver mouse from apoptosis and improves behavioral phenotype. J Biol Chem 277: 44285-44291.
62. Yadava N, Houchens T, Potluri P, Scheffler IE (2004) Development and characterization of a conditional mitochondrial complex I assembly system. J Biol Chem 279: 12406-12413.